Ann: Two more PANCOSIL Trial treatments using OncoSil device, page-184

Strong finish to the week , prior to open there were approximately 30 million on the bid at 0.004 and 27 million on the ask at 0.005. It was actually closer to 40 million on the ask Offer but was reduced or taken off screen prior to open. The vast majority of buying was done by buying the ask which was on offer and not by dumping. Great to see buyers actually buying the ask , offer rather than dumping into the bid.

The Biotech sector is brutal but look at examples such as DXB well over 30 cents decimated back closer to 5 cents , now back at or over 30 cents , similar to BOT. There are many examples. A turnaround is possible. They seem to be busy so updates are going to be released when available.



OSPREY is a post-market, global, multicentre, observational, prospective registry in which data is recorded from patients who undergo OncoSil™ device implantation.

Countries intended for initial commercial distribution include Australia, Belgium, France, Germany, Italy, Singapore, Spain, & the United Kingdom.

Only patients who are intended to undergo treatment with the OncoSil™ device in the commercial (sales) setting will participate in this Registry.